{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:42:03Z","timestamp":1761972123248,"version":"build-2065373602"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.2169\/internalmedicine.4884-24","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:07:43Z","timestamp":1744999663000},"page":"3130-3134","source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Refractory TAFRO Syndrome with Cyclophosphamide: A Report of Two Cases"],"prefix":"10.2169","volume":"64","author":[{"given":"Kaito","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Teine Keijinkai Hospital, Japan"},{"name":"Department of Rheumatology, Teine Keijinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Teine Keijinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Pathology, Teine Keijinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Teine Keijinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki (Jpn J Clin Hematol) 51: 320-325, 2010 (in Japanese)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. J Clin Exp Hematop 53: 63-68, 2013.","DOI":"10.3960\/jslrt.53.63"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103: 686-692, 2016.","DOI":"10.1007\/s12185-016-1979-1"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132: 2115-2124, 2018.","DOI":"10.1182\/blood-2018-07-862334"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol 96: 1241-1252, 2021.","DOI":"10.1002\/ajh.26292"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishimura Y, Nishimura MF, Sato Y. International definition of iMCD-TAFRO: future perspectives. J Clin Exp Hematop 62: 73-78, 2022.","DOI":"10.3960\/jslrt.21037"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91: 220-226, 2016.","DOI":"10.1002\/ajh.24242"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Masaki Y, Kawabata H, Takai K, et al.; Japanese TAFRO Syndrome Research Team. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111: 155-158, 2020.","DOI":"10.1007\/s12185-019-02780-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhang L, Dong YJ, Peng HL, et al.; the China Castleman Disease Network (CCDN). A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. Lancet Reg Health West Pac 34: 100720, 2023.","DOI":"10.1016\/j.lanwpc.2023.100720"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki K, Nakamura K, Kasuya T, et al. Case Report: A case of TAFRO syndrome successfully treated with intravenous cyclophosphamide therapy. Nihon Naika Gakkai Zasshi (J Jpn Soc Int Med) 105: 2417-2425, 2016 (in Japanese).","DOI":"10.2169\/naika.105.2417"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kikuchi T, Shimizu T, Toyama T, Abe R, Okamoto S. Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56: 2205-2211, 2017.","DOI":"10.2169\/internalmedicine.8522-16"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yanagiya R, Suzuki T, Nakamura S, et al. TAFRO syndrome presenting with retroperitoneal panniculitis-like computed tomography findings at disease onset. Intern Med 59: 997-1000, 2020.","DOI":"10.2169\/internalmedicine.3740-19"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kawabata H, Fujimoto S, Sakai T, et al. Patient&apos;s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol 114: 179-188, 2021.","DOI":"10.1007\/s12185-021-03159-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Xia P, Zhang L, Zou M, et al. Acute kidney injury caused by TAFRO syndrome in a Chinese patient: efficacy of long-term corticosteroids combined with bortezomib and cyclophosphamide. Kidney Blood Press Res 45: 623-630, 2020.","DOI":"10.1159\/000505458"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129: 4451-4463, 2019.","DOI":"10.1172\/JCI126091"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Iwaki N, Gion Y, Kondo E, et al. Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep 7: 42316, 2017.","DOI":"10.1038\/srep42316"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pierson SK, Katz L, Williams R, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun 13: 7236, 2022.","DOI":"10.1038\/s41467-022-34873-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a &quot;chemokine storm&quot; in idiopathic multicentric Castleman disease. Am J Hematol 93: 902-912, 2018.","DOI":"10.1002\/ajh.25123"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ota M, Iwasaki Y, Harada H, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol 27: 22-28, 2017.","DOI":"10.3109\/14397595.2016.1173816"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Diehl R, Ferrara F, M\u00fcller C, et al. Immunosuppression for <i>in vivo<\/i> research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 14: 146-179, 2017.","DOI":"10.1038\/cmi.2016.39"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 79: 1082-1090, 1987.","DOI":"10.1172\/JCI112922"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Calder\u00f3n-Parra J, M\u00fa\u00f1ez-Rubio E, Fern\u00e1ndez-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis 74: 1786-1794, 2022.","DOI":"10.1093\/cid\/ciab700"},{"key":"23","unstructured":"23. Landew\u00e9 RB, Kroon FP, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 81: 1628-1639, 2022."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Maneikis K, \u0160ablauskas K, Ringelevi\u010di\u016bt\u0117 U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 8: e583-e592, 2021.","DOI":"10.1016\/S2352-3026(21)00169-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fujimoto S, Kawabata H, Sakai T, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol 113: 73-80, 2021.","DOI":"10.1007\/s12185-020-03008-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_4884-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:26:34Z","timestamp":1761967594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_4884-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":25,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4884-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"4884-24"}}